skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples

Clone-directed therapy for proliferative glomerulonephritis with monoclonal immunoglobulin depositions: is it always necessary?

van Kruijsdijk, Rob C. M. ; Abrahams, Alferso C. ; Nguyen, Tri Q. ; Minnema, Monique C. ; Jacobs, Joannes F. M. ; Limper, Maarten

Journal of nephrology, 2020-01, Vol.33 (3), p.611-617 [Periódico revisado por pares]

Cham: Springer International Publishing

Texto completo disponível

Citações Citado por
  • Título:
    Clone-directed therapy for proliferative glomerulonephritis with monoclonal immunoglobulin depositions: is it always necessary?
  • Autor: van Kruijsdijk, Rob C. M. ; Abrahams, Alferso C. ; Nguyen, Tri Q. ; Minnema, Monique C. ; Jacobs, Joannes F. M. ; Limper, Maarten
  • Assuntos: Case Report
  • É parte de: Journal of nephrology, 2020-01, Vol.33 (3), p.611-617
  • Descrição: Monoclonal gammopathy of renal significance (MGRS) encompasses a group of disorders in which a monoclonal immunoglobulin (M-protein) secreted by a B-cell or plasma cell clone causes renal disease. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a form of MGRS where M-protein is deposited in the glomerulus. Although evidence is limited, the current consensus is that therapy for PGNMID should be directed against the underlying clone. However, it is conceivable that there is heterogeneity in the renal prognosis of PGNMID and that not all patients have need for clone-directed therapy. Here, we report two cases of PGNMID with IgM-kappa gammopathy. In one case of a 53-year-old woman the glomerulonephritis resolved without clone-directed therapy. In the other case of a 34-year-old woman clone-directed therapy was discontinued due to adverse effects. Although no hematological response was achieved, the PGNMID resolved. In both cases there are no signs of a recurrent glomerulonephritis in over 3 years of follow-up. Here, we review the literature and suggest that some PGNMID patients have a favorable renal prognosis in whom clone-directed therapy can be withheld or postponed. Further research is warranted to yield predictors to identify these patients and to better understand the disease course of PGNMID.
  • Editor: Cham: Springer International Publishing
  • Idioma: Inglês
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  4 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.